Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore

thehindubusinessline.com · 2026-09-07

Novartis India acquires BP drug trademarks from Pfizer for ₹1,250 crore, following ChrysCapital's stake acquisition.

TickrTrends take: Pfizer's divestiture of BP drug trademarks to Novartis India represents a strategic portfolio rationalization in a competitive market segment. Given TickrTrends' current assessment that PFE is overvalued, investors should monitor whether such asset sales contribute to improved cash flow metrics or signal a broader shift in capital allocation strategy that could affect the company's valuation multiples. The transaction underscores ongoing portfolio optimization in the Healthcare sector, which typically reflects management's response to market positioning and profitability pressures on legacy product lines.

Read the full story at thehindubusinessline.com →